Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959815 · ClinicalTrials.gov registry record
Novel Screening Strategies for Scleroderma PAH
A clinical trial of Pulmonary Arterial Hypertension and Scleroderma, sponsored by University of Michigan.
- Completed
- Registry status
- 156
- Enrollment target
- 1
- Study location
NCT01959815: Completed study of Pulmonary Arterial Hypertension and Scleroderma, sponsored by University of Michigan.
NCT01959815 is a study of Pulmonary Arterial Hypertension and Scleroderma that has completed, run by University of Michigan. The registered enrollment target is 156 participants, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01959815, a study of Pulmonary Arterial Hypertension and Scleroderma, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with scleroderma can develop heart failure due to high blood pressure in the lungs (a condition called pulmonary arterial hypertension). It is important to find pulmonary arterial hypertension early, so that it can be treated before heart failure develops. However, the tests that we now use to find the earliest form of this disease in scleroderma patients are not good enough. This study will examine whether tests performed during exercise can improve our ability to find early pulmonary arterial hypertension. The study will also try to identify genes that are responsible for the development of pulmonary arterial hypertension.
Conditions Studied
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2013-09-26 |
| Est. Completion | 2019-11-06 |
What the finished NCT01959815 record still lists
NCT01959815 is an observational study that tracks outcomes without assigning an intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 460-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT01959815 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01959815 about?
NCT01959815 is a clinical study titled "Novel Screening Strategies for Scleroderma PAH". Patients with scleroderma can develop heart failure due to high blood pressure in the lungs (a condition called pulmonary arterial hypertension). It is important to find pulmonary arterial hypertension early, so that it can be treated before heart failure develops. However, the tests that we now use...
What is the current status of trial NCT01959815?
This trial is currently completed. The enrollment target is 156 participants. The study started on 2013-09-26. Estimated completion is 2019-11-06.
What conditions does trial NCT01959815 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension, Scleroderma.
Who is sponsoring clinical trial NCT01959815?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01959815 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01959815's enrollment target sits among peer trials
156 15th of 63 higher than 49 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI